This article is more than 5 years old. Information may no longer be current.

Alcon’s first quarter earnings, sales increase

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Alcon’s global sales during the first quarter increased 14.2% while net earnings increased 38.5% to $130.2 million, compared to the company’s first quarter sales and earnings in 2002.

Pharmaceutical sales grew 21.9% to $302.6 million in the first quarter of the year. Total sales of glaucoma products increased to $101.6 million, led by sales of Travatan (travoprost). Sales of ocular infection and anti-inflammation therapies grew 16.1% to $126.1 million. Allergy product sales grew to $56.6 million in the quarter, led by a significant increase in Patanol prescriptions (olopatadine hydrochloride ophthalmic solution). The company’s surgical product line sales grew 11.7%. Alcon’s IOL sales increased 15.7% to $117.6 million. Cataract and vitrectomy equipment sales grew to $240.8 million. Sales of refractive surgery products decreased 6.6%.

A company news release indicated that net earnings would have grown 20.3% had the company not taken a tax charge because of its initial public offering in March 2002.